Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma

Adam N. Mamelak, Steven Rosenfeld, Richard Bucholz, Andrew Raubitschek, L. Burt Nabors, John B. Fiveash, Sui Shen, M. B. Khazaeli, David Colcher, An Liu, Medhat Osman, Bart Guthrie, Susan Schade-Bijur, Diana M. Hablitz, Vernon L. Alvarez, Matthew A. Gonda

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Purpose: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma. Patients and Methods: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of a 60% who were eligible for cytoreductive craniotomy were enrolled. An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery. Two weeks after surgery, patients received a single dose of 131I-TM-601 from one of three dosing panels (0.25, 0.50, or 1.0 mg of TM-601), each labeled with 10 mCi of 131I. Results: Intracavitary administration was well tolerated, with no dose-limiting toxicities observed. 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system. Nonbound peptide was eliminated from the body within 24 to 48 hours. Only minor adverse events were reported during the 22 days after administration. At day 180, four patients had radiographic stable disease, and one had a partial response. Two of these patients further improved and were without evidence of disease for more than 30 months. Conclusion: A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect. Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.

Original languageEnglish (US)
Pages (from-to)3644-3650
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number22
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Glioma
Iodine
Karnofsky Performance Status
Chlorotoxin
Neoplasms
Craniotomy
Astrocytoma
Glioblastoma
Brain Neoplasms
Catheters
Safety
Peptides
Brain
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. / Mamelak, Adam N.; Rosenfeld, Steven; Bucholz, Richard; Raubitschek, Andrew; Nabors, L. Burt; Fiveash, John B.; Shen, Sui; Khazaeli, M. B.; Colcher, David; Liu, An; Osman, Medhat; Guthrie, Bart; Schade-Bijur, Susan; Hablitz, Diana M.; Alvarez, Vernon L.; Gonda, Matthew A.

In: Journal of Clinical Oncology, Vol. 24, No. 22, 01.08.2006, p. 3644-3650.

Research output: Contribution to journalArticle

Mamelak, AN, Rosenfeld, S, Bucholz, R, Raubitschek, A, Nabors, LB, Fiveash, JB, Shen, S, Khazaeli, MB, Colcher, D, Liu, A, Osman, M, Guthrie, B, Schade-Bijur, S, Hablitz, DM, Alvarez, VL & Gonda, MA 2006, 'Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma', Journal of Clinical Oncology, vol. 24, no. 22, pp. 3644-3650. https://doi.org/10.1200/JCO.2005.05.4569
Mamelak, Adam N. ; Rosenfeld, Steven ; Bucholz, Richard ; Raubitschek, Andrew ; Nabors, L. Burt ; Fiveash, John B. ; Shen, Sui ; Khazaeli, M. B. ; Colcher, David ; Liu, An ; Osman, Medhat ; Guthrie, Bart ; Schade-Bijur, Susan ; Hablitz, Diana M. ; Alvarez, Vernon L. ; Gonda, Matthew A. / Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 22. pp. 3644-3650.
@article{94b63f55b55f49f19850409db5c52755,
title = "Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma",
abstract = "Purpose: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma. Patients and Methods: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of a 60{\%} who were eligible for cytoreductive craniotomy were enrolled. An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery. Two weeks after surgery, patients received a single dose of 131I-TM-601 from one of three dosing panels (0.25, 0.50, or 1.0 mg of TM-601), each labeled with 10 mCi of 131I. Results: Intracavitary administration was well tolerated, with no dose-limiting toxicities observed. 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system. Nonbound peptide was eliminated from the body within 24 to 48 hours. Only minor adverse events were reported during the 22 days after administration. At day 180, four patients had radiographic stable disease, and one had a partial response. Two of these patients further improved and were without evidence of disease for more than 30 months. Conclusion: A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect. Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.",
author = "Mamelak, {Adam N.} and Steven Rosenfeld and Richard Bucholz and Andrew Raubitschek and Nabors, {L. Burt} and Fiveash, {John B.} and Sui Shen and Khazaeli, {M. B.} and David Colcher and An Liu and Medhat Osman and Bart Guthrie and Susan Schade-Bijur and Hablitz, {Diana M.} and Alvarez, {Vernon L.} and Gonda, {Matthew A.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1200/JCO.2005.05.4569",
language = "English (US)",
volume = "24",
pages = "3644--3650",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma

AU - Mamelak, Adam N.

AU - Rosenfeld, Steven

AU - Bucholz, Richard

AU - Raubitschek, Andrew

AU - Nabors, L. Burt

AU - Fiveash, John B.

AU - Shen, Sui

AU - Khazaeli, M. B.

AU - Colcher, David

AU - Liu, An

AU - Osman, Medhat

AU - Guthrie, Bart

AU - Schade-Bijur, Susan

AU - Hablitz, Diana M.

AU - Alvarez, Vernon L.

AU - Gonda, Matthew A.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Purpose: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma. Patients and Methods: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of a 60% who were eligible for cytoreductive craniotomy were enrolled. An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery. Two weeks after surgery, patients received a single dose of 131I-TM-601 from one of three dosing panels (0.25, 0.50, or 1.0 mg of TM-601), each labeled with 10 mCi of 131I. Results: Intracavitary administration was well tolerated, with no dose-limiting toxicities observed. 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system. Nonbound peptide was eliminated from the body within 24 to 48 hours. Only minor adverse events were reported during the 22 days after administration. At day 180, four patients had radiographic stable disease, and one had a partial response. Two of these patients further improved and were without evidence of disease for more than 30 months. Conclusion: A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect. Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.

AB - Purpose: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma. Patients and Methods: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of a 60% who were eligible for cytoreductive craniotomy were enrolled. An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery. Two weeks after surgery, patients received a single dose of 131I-TM-601 from one of three dosing panels (0.25, 0.50, or 1.0 mg of TM-601), each labeled with 10 mCi of 131I. Results: Intracavitary administration was well tolerated, with no dose-limiting toxicities observed. 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system. Nonbound peptide was eliminated from the body within 24 to 48 hours. Only minor adverse events were reported during the 22 days after administration. At day 180, four patients had radiographic stable disease, and one had a partial response. Two of these patients further improved and were without evidence of disease for more than 30 months. Conclusion: A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect. Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.

UR - http://www.scopus.com/inward/record.url?scp=33747059059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747059059&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.05.4569

DO - 10.1200/JCO.2005.05.4569

M3 - Article

VL - 24

SP - 3644

EP - 3650

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -